Oncology division

[anonymous]

I heard a rumor so take it as that. Eiasi is thinking about closing the oncology part and giving it to another company and just taking the profits while having no oncology employees or risk.

I have heard this before. Without anything new coming, why not. Eisai would be more profitable without any sales people to pay or benefits and the risk being taken by someone else. You sure don't see any new people being hired to launch a new product do you! Tory and the management team are clueless.

 

[anonymous]

I have heard this before. Without anything new coming, why not. Eisai would be more profitable without any sales people to pay or benefits and the risk being taken by someone else. You sure don't see any new people being hired to launch a new product do you! Tory and the management team are clueless.

Several decades ago, Japanese companies usually just licensed their products to a western firm to promote on their behalf. They were wise enough to acknowledge they didn’t have the intelligence, experience, knowledge or acumen to compete effectively in the US market. It’s probably time to get back to that.

 

[anonymous]

Alex Scott did the dude.

 

[anonymous]

Several decades ago, Japanese companies usually just licensed their products to a western firm to promote on their behalf. They were wise enough to acknowledge they didn’t have the intelligence, experience, knowledge or acumen to compete effectively in the US market. It’s probably time to get back to that.

There are no Jap pharma companies that are considered world class. That definitely applies to Eisai.

 

[anonymous]

I think we are about to shut this mother down

 

[anonymous]

I think we are about to shut this mother down

Think they will sell off Lenvima? I could see that, while it’s still profitable but not very exciting.

 

[anonymous]

Who wold buy it? I hear Merck doesn't want it or need it, it's too small of drug.

 

[anonymous]

Think they will sell off Lenvima? I could see that, while it’s still profitable but not very exciting.

Well, seeing that our “Partner” Merck just inked a research collaboration with our competitor, it doesn’t look good..,

 

[anonymous]

Well, seeing that our “Partner” Merck just inked a research collaboration with our competitor, it doesn’t look good..,

No, oncology companies are always doing partnerships with multiple competitors. Doesn’t mean anything

 

[anonymous]

Pray for the Japs.

 

[anonymous]

No, oncology companies are always doing partnerships with multiple competitors. Doesn’t mean anything

Yeah? Really? Name one in the exact same class/MOA, where one of the companies owns a 40% interest in revenue of the other.
Merck could have easily done that collaboration with us and Len. They chose not to.

Stop trying to paint this positive picture. It’s laughable.

 

[anonymous]

No, oncology companies are always doing partnerships with multiple competitors. Doesn’t mean anything

Guess you are not listening to the EXEL earnings call...they are kicking our ass and now our 'companion drug' is partnering with their new TKI...yeah sounds like all good news for Eisai. Keep drinking the Kool-Aid...

"8 consecutive quarters of Nivo/Cabo being the #1 prescribed IO/TKI combo in RCC". #1 TKI in RCC and we are not even close.

Oncology is dead here.

 

[anonymous]

Guess you are not listening to the EXEL earnings call...they are kicking our ass and now our 'companion drug' is partnering with their new TKI...yeah sounds like all good news for Eisai. Keep drinking the Kool-Aid...

"8 consecutive quarters of Nivo/Cabo being the #1 prescribed IO/TKI combo in RCC". #1 TKI in RCC and we are not even close.

Oncology is dead here.

Ok ok geeze it’s not good. So many bullies at this company! Sounds like next year will be a good time to look.

 

[anonymous]

Eisai isn’t stupid. They will have another collaboration or indication soon. Just watch

 

[anonymous]

Eisai isn’t stupid. They will have another collaboration or indication soon. Just watch

Sure. New drug for sushi breath

 

[anonymous]

Eisai isn’t stupid. They will have another collaboration or indication soon. Just watch

Not quite. Eisai is the short school bus of the pharma industry.

 

[anonymous]

Eisai isn’t stupid. They will have another collaboration or indication soon. Just watch

Good one…

 

[anonymous]

Eisai is a punchline.

 

[anonymous]

This place is going out of the oncology. I finally broke down and call a recruiter today to beging the search, it's time to leave. I have been here a long time and its unsettling looking for a job.

 

[anonymous]

This place is going out of the oncology. I finally broke down and call a recruiter today to beging the search, it's time to leave. I have been here a long time and its unsettling looking for a job.

Eisai is in the oncology?